MicroRNA Signature of Primary Pigmented Nodular Adrenocortical Disease: Clinical Correlations and Regulation of Wnt Signaling

被引:66
|
作者
Iliopoulos, Dimitrios [2 ]
Bimpaki, Eirini I. [1 ]
Nesterova, Maria [1 ]
Stratakis, Constantine A. [1 ]
机构
[1] NICHHD, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA
[2] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
关键词
CARNEY COMPLEX; EXPRESSION; TUMORS; HYPERPLASIAS; PATHWAYS; MUTATION; GENES;
D O I
10.1158/0008-5472.CAN-09-0155
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs comprise a novel group of gene regulators implicated in the development of different types of cancer; however, their role in primary pigmented nodular adrenocortical disease (PPNAD) has not been investigated. PPNAD is a bilateral adrenal hyperplasia often associated with Carney complex, a multiple neoplasia syndrome; both disorders are caused by protein kinase A (PKA) regulatory subunit type 1A (PRKARIA)-inactivating mutations. We identified a 44-microRNA gene signature of PPNAD after comparing PPNAD with normal adrenal samples. Specifically, 33 microRNAs were up-regulated and 11 down-regulated in PPNAD relative to normal tissues. These results were validated by stem loop real-time PCR analysis. Comparison of microRNA microarray data with clinicopathologic variables revealed a negative correlation (r = -0.9499) between let-7b expression and cortisol levels in patients with PPNAD. Integration of microRNA microarray with serial analysis of gene expression data together with bioinformatic algorithm predictions revealed nine microRNA-gene target pairs with a potential role in adrenal pathogenesis. Using a PPNAD cell line, we showed that miR-449 was up-regulated and identified its direct target, WNT1-inducible signaling pathway protein 2 (WISP2); in addition, pharmacologic inhibition of PKA resulted in the up-regulation of miR-449 leading to the suppression of WISP2. Overall, we investigated, for the first time, the microRNA profile and its clinical significance in PPNAD; these data also suggest that PKA, via microRNA regulation, affects the Writ signaling pathway, which through expression and clinical studies is suspected to be a primary mediator of PRKAR1A-related tumorigenesis. [Cancer Res 2009;69(8):3278-82]
引用
收藏
页码:3278 / 3282
页数:5
相关论文
共 50 条
  • [21] MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumourigenesis
    Bimpaki, Eirini I.
    Iliopoulos, Dimitrios
    Moraitis, Andreas
    Stratakis, Constantine A.
    CLINICAL ENDOCRINOLOGY, 2010, 72 (06) : 744 - 751
  • [22] Causes and consequences of abandoning one-stage bilateral adrenalectomy recommended in primary pigmented nodular adrenocortical disease - case presentation
    Kumorowicz-Czoch, Malgorzata
    Dolezal-Oltarzewska, Katarzyna
    Roztoczynska, Dorota
    Chrupek, Malgorzata
    Prokurat, Andrzej Igor
    Drabik, Grazyna
    Starzyk, Jerzy
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2011, 24 (7-8): : 565 - 567
  • [23] Primary pigmented nodular adrenocortical disease: literature review and case report of a 6-year-old boy
    Katanic, Dragan
    Kafka, Dejan
    Zivojinov, Mirjana
    Vlaski, Jovan
    Budakov, Zorana
    Pogancev, Marija Knezevic
    Vorgucin, Ivana
    Cuk, Tomislav
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2017, 30 (05): : 603 - 609
  • [24] Association of the M1V PRKAR1A Mutation with Primary Pigmented Nodular Adrenocortical Disease in Two Large Families
    Pereira, Alberto M.
    Hes, Frederik J.
    Horvath, Anelia
    Woortman, Sanne
    Greene, Elizabeth
    Bimpaki, Eirini
    Alatsatianos, Anton
    Boikos, Sosipatros
    Smit, Johannes W.
    Romijn, Johannes A.
    Nesterova, Maria
    Stratakis, Constantine A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (01): : 338 - 342
  • [25] Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway
    Gokhale, Amit
    Kunder, Ratika
    Goel, Atul
    Sarin, Rajiv
    Moiyadi, Aliasgar
    Shenoy, Asha
    Mamidipally, Chandrasekhar
    Noronha, Santosh
    Kannan, Sadhana
    Shirsat, Neelam Vishwanath
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2010, 6 (04) : 521 - 529
  • [26] Corticotropinoma as the underlying cause of intermittent Cushing's syndrome in a patient previously diagnosed with primary pigmented nodular adrenocortical disease
    Lebek-Szatanska, Agnieszka
    Stelmachowska-Banas, Maria
    Zielinski, Grzegorz
    Styk, Andrzej
    Nowak, Karolina M.
    Papierska, Lucyna
    ENDOKRYNOLOGIA POLSKA, 2020, 71 (03) : 273 - 274
  • [27] Use of 3-Dimensional Volumetric Modeling of Adrenal Gland Size in Patients with Primary Pigmented Nodular Adrenocortical Disease
    Chrysostomou, P. P.
    Lodish, M. B.
    Turkbey, E. B.
    Papadakis, G. Z.
    Stratakis, C. A.
    HORMONE AND METABOLIC RESEARCH, 2016, 48 (04) : 242 - 246
  • [28] Efficacy of dexamethasone suppression test during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing syndrome
    Chen, Shi
    Li, Ran
    Lu, Lin
    Duan, Lian
    Zhang, Xuebin
    Tong, Anli
    Pan, Hui
    Zhu, Huijuan
    Lu, Zhaolin
    ENDOCRINE, 2018, 59 (01) : 183 - 190
  • [29] The Paradoxical Increase in Cortisol Secretion Induced by Dexamethasone in Primary Pigmented Nodular Adrenocortical Disease Involves a Glucocorticoid Receptor-Mediated Effect of Dexamethasone on Protein Kinase A Catalytic Subunits
    Louiset, Estelle
    Stratakis, Constantine A.
    Perraudin, Veronique
    Griffin, Kurt J.
    Libe, Rossella
    Cabrol, Sylvie
    Feve, Bruno
    Young, Jacques
    Groussin, Lionel
    Bertherat, Jerome
    Lefebvre, Herve
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (07): : 2406 - 2413
  • [30] Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: the NIH studies
    Stratakis, C. A.
    HORMONE AND METABOLIC RESEARCH, 2007, 39 (06) : 467 - 473